Navigation Links
Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
Date:10/16/2007

site techniques. For more information on PGDIS, go to http://www.pgdis.org. PGDIS holds open international meetings, the next one which is April 25-27 in Barcelona, Spain.

About PGDIS:

PGDIS coordinates research, education and training in preimplantation genetic diagnosis (PGD), requiring a close collaboration of obstetricians, fertility specialists, embryologists and human geneticists, to insure safety and accuracy of PGD and its application into clinical practice for improvement of genetic practices and reproductive medicine.

PGDIS was organized in October 2002 and inaugurated during the 5th International Symposium on Preimplantation Genetics, Antalya, Turkey, June 5-7, 2003.

Founding Members of PGDIS are the participants of the 4th International Symposium on Preimplantation Genetics, Limassol, Cyprus, 2002; and 5th International Symposium on Preimplantation Genetics, Antalia, Turkey, 2003.

The official Journal of PGDIS is Reproductive BioMedicine Online, which has recently published many papers in this field.


'/>"/>
SOURCE The Preimplantation Genetic Diagnosis InternationalSociety (PGDIS)
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
4. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
5. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
6. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
7. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
8. Researchers Identify New Genetic Risk Factors for Type 2 Diabetes
9. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
10. Myriad Genetics Presents Tumor Origin Technology at AACR
11. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Confusion Over Homeopathic Medicines in Alexa Ray Joel's Hospitalization Clarified by the American Association of Homeopathic Pharmacists (AAHP) 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 1Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 2Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 3Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 4Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 1Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 2Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 3Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 4Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 5Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 6Study finds cancer is the second most frequent cause of death in individuals with schizophrenia 49558 1Study finds cancer is the second most frequent cause of death in individuals with schizophrenia 49558 2